Advent Venture Partners has named Dale Pfost as a venture partner.
Pfost previously served as CEO and chairman of Acuity Pharmaceuticals, an siRNA-based drug developer that was later acquired by Opko Health.
Regulus Therapeutics has promoted Garry Menzel to COO and executive vice president of finance.
He previously served as executive vice president of corporate development and finance. Before joining Regulus, Menzel was a managing director at Credit Suisse. Before that, he was a managing director at Goldman Sachs.
He has a BSc in biochemistry from the Imperial College of Science & Technology, and a PhD in molecular biology from the University of Cambridge. He also received an MBA from the Stanford Graduate School of Business.